QLT091001
Sponsors
QLT Inc.
Conditions
Healthy Human VolunteersImpaired Dark AdaptationLCA (Leber Congenital Amaurosis)RP (Retinitis Pigmentosa)Retinitis Pigmentosa (RP)
Phase 1
Safety and Tolerability of Retinoid QLT091001 in Healthy Volunteers
CompletedNCT00765427
Start: 2008-09-30End: 2009-03-31Target: 18Updated: 2009-03-30
Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations
CompletedNCT01014052
Start: 2009-11-30End: 2012-08-31Updated: 2013-05-14
Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)
CompletedNCT01521793
Start: 2012-01-31End: 2014-06-30Updated: 2014-07-28
Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)
CompletedNCT01543906
Start: 2012-02-29End: 2014-08-31Updated: 2014-12-15